litlas
Log inCreate account

Stephan Stilgenbauer

Active 1993–2026

284
Papers
51,371
Citations
120
h-index
270
i10-index

Citations

Citations per year for Stephan Stilgenbauer1976: 1 citations1993: 1 citations1994: 4 citations1995: 6 citations1996: 9 citations1997: 30 citations1998: 32 citations1999: 76 citations2000: 85 citations2001: 102 citations2002: 171 citations2003: 158 citations2004: 153 citations2005: 197 citations2006: 188 citations2007: 186 citations2008: 230 citations2009: 203 citations2010: 254 citations2011: 255 citations2012: 261 citations2013: 237 citations2014: 369 citations2015: 452 citations2016: 364 citations2017: 466 citations2018: 520 citations2019: 1,456 citations2020: 1,762 citations2021: 1,664 citations2022: 1,204 citations2023: 925 citations2024: 1,616 citations2025: 707 citations2026: 42 citations1977–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,257 citing papers, 23.9% of this breakdownGermany: 1,267 citing papers, 9.3% of this breakdownUnited Kingdom: 1,005 citing papers, 7.4% of this breakdownChina: 994 citing papers, 7.3% of this breakdownItaly: 889 citing papers, 6.5% of this breakdownFrance: 641 citing papers, 4.7% of this breakdownSpain: 540 citing papers, 4% of this breakdownCanada: 416 citing papers, 3.1% of this breakdownNetherlands: 410 citing papers, 3% of this breakdownAustralia: 400 citing papers, 2.9% of this breakdownSwitzerland: 369 citing papers, 2.7% of this breakdownSweden: 292 citing papers, 2.1% of this breakdown
0%23.9%Other 23.1%

Institutions

Fields

  • Medicine66.9%
  • Biochemistry, Genetics and Molecular Biology26.9%
  • Immunology and Microbiology3.5%
  • Neuroscience0.8%
  • Computer Science0.5%
  • Chemistry0.5%
  • Other0.9%

Topics

  • Chronic Lymphocytic Leukemia Research14.2%
  • Lymphoma Diagnosis and Treatment11.8%
  • Immunodeficiency and Autoimmune Disorders3.7%
  • CAR-T cell therapy research2.9%
  • Chronic Myeloid Leukemia Treatments2.1%
  • Viral-associated cancers and disorders1.9%
  • Other63.4%

Coauthors

All papers

Open in search
  1. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Authors: Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris‐Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael J. Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, Thomas J. Kipps - Blood 2018 cited by 1,689

  2. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

    Authors: John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O’Brien, Mustafa Nuri Yenerel, Árpád Illés, Neil E. Kay, José A. García‐Marco, Anthony R. Mato, Javier Pinilla‐Ibarz, John F. Seymour, Stéphane Leprêtre, Stephan Stilgenbauer, Tadeusz Robak, Wayne Rothbaum, Raquel Izumi, Ahmed Hamdy, Priti Patel, Kara Higgins, Sophia Sohoni, Wojciech Jurczak - Journal of Clinical Oncology 2021 cited by 635

  3. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

    Authors: Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater, Moritz Fürstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar da Cunha‐Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Thomas Nösslinger, Ann Janssens, Ilse Christiansen, Michaël Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jäger, Maria B. L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry R. Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna‐Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens‐Martin Wendtner, Karl Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark‐David Levin, Marinus van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek - New England Journal of Medicine 2023 cited by 291

  4. Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

    Authors: Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu, Hatice Gülçin Özer, Marc Zapatka, Amy S. Ruppert, Ling Xue, Daniel Hsieh-Hsin Li, Susanne Steggerda, Matthias Versele, Sandeep S. Davé, Jenny Zhang, Ayse Selen Yilmaz, Samantha Jaglowski, Kristie A. Blum, Arletta Lozanski, Gerard Lozanski, Danelle F. James, Jacqueline C. Barrientos, Peter Lichter, Stephan Stilgenbauer, Joseph J. Buggy, Betty Chang, Amy J. Johnson, John C. Byrd - New England Journal of Medicine 2014 cited by 1,254

  5. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    Authors: Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo, Anna‐Maria Fink, Maneesh Tandon, Mark Dixon, Sandra Robrecht, Simon Warburton, Kathryn Humphrey, Olga Samoylova, A. M. Liberati, Javier Pinilla‐Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura Fogliatto, Carsten Utoft Niemann, Robert Weinkove, Sue Robinson, Thomas J. Kipps, Sebastian Böettcher, Eugen Tausch, Rod Humerickhouse, Barbara Eichhorst, Clemens‐Martin Wendtner, Anton W. Langerak, Karl-Anton Kreuzer, Matthias Ritgen, Valentin Goede, Stephan Stilgenbauer, Mehrdad Mobasher, Michael Hallek - New England Journal of Medicine 2019 cited by 852

  6. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

    Authors: Michael Wang, Simon Rule, Peter Martin, André Goy, Rebecca Auer, Brad S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, W Wiktor-Jędrzejczak, Peter Johnson, Stephen E. Spurgeon, Lei Li, Liang Zhang, Kate J. Newberry, Zhishuo Ou, Nancy Cheng, Bingliang Fang, Jesse McGreivy, Fong Clow, Joseph J. Buggy, Betty Chang, Darrin M. Beaupre, Lori Kunkel, Kristie A. Blum - New England Journal of Medicine 2013 cited by 1,687

  7. Mutations driving CLL and their evolution in progression and relapse

    Authors: Dan A. Landau, Eugen Tausch, Amaro Taylor‐Weiner, Chip Stewart, Johannes G. Reiter, Jasmin Bahlo, Sandra Kluth, Ivana Božić, Mike Lawrence, Sebastian Böttcher, Scott L. Carter, Kristian Cibulskis, Daniel Mertens, Carrie Sougnez, Mara Rosenberg, Julian M. Hess, Jennifer Edelmann, Sabrina Kless, Michael Kneba, Matthias Ritgen, Anna Maria Fink, Kirsten Fischer, Stacey Gabriel, Eric S. Lander, Martin A. Nowak, Hartmut Döhner, Michael Hallek, Donna Neuberg, Gad Getz, Stephan Stilgenbauer, Catherine J. Wu - Nature 2015 cited by 1,078

  8. Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia

    Authors: Hartmut Döhner, Stephan Stilgenbauer, Axel Benner, Elke Leupolt, Alexander Kröber, Lars Bullinger, Konstanze Döhner, Martin Bentz, Peter Lichter - New England Journal of Medicine 2000 cited by 3,296

  9. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

    Authors: Richard R. Furman, Jeff P. Sharman, Steven Coutré, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger Dansey, Michael Hallek, Susan O’Brien - New England Journal of Medicine 2014 cited by 1,684

  10. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia

    Authors: Eugen Tausch, William Close, Anna Dolnik, Johannes Bloehdorn, Brenda Chyla, Lars Bullinger, Hartmut Döhner, Daniel Mertens, Stephan Stilgenbauer - Haematologica 2019 cited by 203

  11. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

    Authors: Valentin Goede, Kirsten Fischer, Raymonde Busch, Anja Engelke, Barbara Eichhorst, Clemens‐Martin Wendtner, Tatiana Chagorova, Javier de la Serna, Marie‐Sarah Dilhuydy, Thomas Illmer, Stephen Opat, Carolyn Owen, Olga Samoylova, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Hartmut Döhner, Anton W. Langerak, Matthias Ritgen, Michael Kneba, Elina Asikanius, Kathryn Humphrey, Michael Wenger, Michael Hallek - New England Journal of Medicine 2014 cited by 1,500

  12. Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity

    Authors: Bola S. Hanna, Laura Llaó Cid, Murat Iskar, Philipp M. Roessner, Lara C. Klett, John Wong, Yashna Paul, Nikolaos Ioannou, Selcen Öztürk, Norman Mack, Verena Kalter, Dolors Colomer, Elı́as Campo, Johannes Bloehdorn, Stephan Stilgenbauer, Sascha Dietrich, Manfred Schmidt, Richard Gabriel, Karsten Rippe, Markus Feuerer, Alan G. Ramsay, Peter Lichter, Marc Zapatka, Martina Seiffert - Immunity 2021 cited by 130

  13. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    Authors: Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutré, John F. Seymour, Talha Munir, Soham D. Puvvada, Clemens‐Martin Wendtner, Andrew W. Roberts, Wojciech Jurczak, Stephen P. Mulligan, Sebastian Böttcher, Mehrdad Mobasher, Ming Zhu, Monali Desai, Brenda Chyla, Maria Verdugo, Sari H. Enschede, Elisa Cerri, Rod Humerickhouse, Gary Gordon, Michael Hallek, William G. Wierda - The Lancet Oncology 2016 cited by 796

  14. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

    Authors: John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan‐Khan, Richard R. Furman, Susan O’Brien, Jennifer R. Brown, Talha Munir, Anthony R. Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach - Blood 2023 cited by 119

  15. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

    Authors: Othman Al‐Sawaf, Can Zhang, Maneesh Tandon, Arijit Sinha, Anna‐Maria Fink, Sandra Robrecht, Olga Samoylova, Anna Marina Liberati, Javier Pinilla‐Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura Fogliatto, Carsten Utoft Niemann, Robert Weinkove, Sue Robinson, Thomas J. Kipps, Eugen Tausch, William Schary, Matthias Ritgen, Clemens‐Martin Wendtner, Karl-Anton Kreuzer, Barbara Eichhorst, Stephan Stilgenbauer, Michael Hallek, Kirsten Fischer - The Lancet Oncology 2020 cited by 327

  16. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

    Authors: Othman Al‐Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl‐Anton Kreuzer, Brenda Chyla, Joseph N. Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer - Nature Communications 2023 cited by 93

  17. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

    Authors: Ian W. Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés, Gabriel Étienne, Julio Delgado, Bryone J. Kuss, Constantine S. Tam, Zoltán Gasztonyi, Fritz Offner, Scott D. Lunin, F. Bosch, Matthew S. Davids, Nicole Lamanna, Ulrich Jaeger, Paolo Ghia, Florence Cymbalista, Craig A. Portell, Alan P Skarbnik, Amanda F. Cashen, David T. Weaver, Virginia Kelly, Barry Turnbull, Stephan Stilgenbauer - Blood 2018 cited by 341

  18. Tumor-derived exosomes modulate PD-L1 expression in monocytes

    Authors: Franziska Haderk, Ralph Schulz, Murat Iskar, Laura Llaó Cid, Thomas Stefan Worst, Karolin V. Willmund, Angela Schulz, Uwe Warnken, Jana Seiler, Axel Benner, Michelle Neßling, Thorsten Zenz, Maria Göbel, Jan Dürig, Sven Diederichs, Jérôme Paggetti, Etienne Moussay, Stephan Stilgenbauer, Marc Zapatka, Peter Lichter, Martina Seiffert - Science Immunology 2017 cited by 292

  19. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

    Authors: Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski, Maurilio Ponzoni, Martina Deckert, Letterio S. Politi, Valter Torri, Christopher P. Fox, Paul La Rosée, Elisabeth Schorb, Achille Ambrosetti, Alexander Röth, Claire Hemmaway, Angela Ferrari, Kim Linton, Roberta Rudà, Mascha Binder, Tobias Pukrop, Monica Balzarotti, Alberto Fabbri, Peter Johnson, Jette Sønderskov Gørløv, Georg Heß, Jens Panse, Francesco Pisani, Alessandra Tucci, Stephan Stilgenbauer, Bernd Hertenstein, Ulrich Keller, Stefan W. Krause, Alessandro Levis, Hans‐Joachim Schmoll, Franco Cavalli, Jürgen Finke, Michele Reni, Emanuele Zucca, Gerald Illerhaus - The Lancet Haematology 2016 cited by 599

  20. Molecular map of chronic lymphocytic leukemia and its impact on outcome

    Authors: Binyamin A. Knisbacher, Ziao Lin, Cynthia K. Hahn, Ferran Nadeu, Martí Duran‐Ferrer, Kristen E. Stevenson, Eugen Tausch, Julio Delgado, Alex Barbera-Mourelle, Amaro Taylor‐Weiner, Pablo Bousquets‐Muñoz, Ander Díaz‐Navarro, Andrew Dunford, Shankara Anand, Helene Kretzmer, Jesús Gutiérrez‐Abril, Sara López-Tamargo, Stacey M. Fernandes, Clare Sun, Mariela Sivina, Laura Z. Rassenti, Christof Schneider, Shuqiang Li, Laxmi Parida, Alexander Meissner, François Aguet, Jan A. Burger, Adrian Wiestner, Thomas J. Kipps, Jennifer R. Brown, Michael Hallek, Chip Stewart, Donna Neuberg, José I. Martín‐Subero, Xosé S. Puente, Stephan Stilgenbauer, Catherine J. Wu, Elı́as Campo, Gad Getz - Nature Genetics 2022 cited by 148

  21. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

    Authors: Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Peter Hillmen, John F. Seymour, Steven Coutré, Wojciech Jurczak, Stephen P. Mulligan, Anna Schuh, Sarit Assouline, Clemens‐Martin Wendtner, Andrew W. Roberts, Matthew S. Davids, Johannes Bloehdorn, Talha Munir, Sebastian Böttcher, Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer A. Arzt, Su Young Kim, Maria Verdugo, Gary Gordon, Michael Hallek, William G. Wierda - Journal of Clinical Oncology 2018 cited by 313

  22. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

    Authors: Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski, Christopher P. Fox, Elisabeth Schorb, Claudia Celico, Monica Falautano, Alessandro Nonis, Paul La Rosée, Mascha Binder, Alberto Fabbri, Fiorella Ilariucci, Mauro Krampera, Alexander Röth, Claire Hemmaway, Peter Johnson, Kim Linton, Tobias Pukrop, Jettes Sønderskov Gørløv, Monica Balzarotti, Georg Heß, Ulrich Keller, Stephan Stilgenbauer, Jense Panse, Alessandra Tucci, Lorella Orsucci, Francesco Pisani, Manuela Zanni, Stefan W. Krause, Hans‐Joachim Schmoll, Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Lorenz Thurner, Giuseppina Cabras, Elsa Pennese, Maurilio Ponzoni, Martina Deckert, Letterio S. Politi, Jürgen Finke, Antonella Ferranti, Kelly Cozens, Elvira Burger, Nicoletta Ielmini, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus, IELSG32 study investigators - Leukemia 2022 cited by 162

  23. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

    Authors: Othman Al‐Sawaf, Can Zhang, Tong Lu, Michael Z. Liao, Anesh Panchal, Sandra Robrecht, Travers Ching, Maneesh Tandon, Anna‐Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Sebastian Böttcher, Karl‐Anton Kreuzer, Brenda Chyla, Dale Miles, Clemens‐Martin Wendtner, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer - Journal of Clinical Oncology 2021 cited by 142

  24. The genomic and transcriptional landscape of primary central nervous system lymphoma

    Authors: Josefine Radke, Naveed Ishaque, Randi Koll, Zuguang Gu, Elisa Schumann, Lina Sieverling, Sebastian Uhrig, Daniel Hübschmann, Umut H. Toprak, Cristina López, Xavier Pastor Hostench, Simone Borgoni, Dilafruz Juraeva, Fabienne Pritsch, Nagarajan Paramasivam, Gnana Prakash Balasubramanian, Matthias Schlesner, Shashwat Sahay, Marc A. Weniger, Debora Pehl, Helena Radbruch, Anja Osterloh, Agnieszka Korfel, Martin Misch, Julia Onken, Katharina Faust, Peter Vajkoczy, Dag Moskopp, Yawen Wang, Andreas Jödicke, Lorenz Trümper, Ioannis Anagnostopoulos, Dido Lenze, Ralf Küppers, Michael Hummel, Clemens A. Schmitt, Otmar D. Wiestler, Stephan Wolf, Andreas Unterberg, Roland Eils, Christel Herold‐Mende, Benedikt Brors, Coordination (C1), Reiner Siebert, Susanne Wagner, Andrea Haake, Julia Richter, Gesine Richter, Roland Eils, Chris Lawerenz, Jürgen Eils, Jules N. A. Kerssemakers, Christina Jaeger-Schmidt, Ingrid Scholz, Anke Bergmann, Christoph Borst, Friederike Braulke, Birgit Burkhardt, Alexander Claviez, Martin Dreyling, Sonja Eberth, Hermann Einsele, Norbert Frickhofen, Siegfried Haas, Martin‐Leo Hansmann, Dennis Karsch, Nicole Klepl, Michael Kneba, Jasmin Lisfeld, Luisa Mantovani‐Löffler, Marius Rohde, German Ott, Christina Stadler, Peter Staib, Stephan Stilgenbauer, Thorsten Zenz, Normal Cells (WPN), Martin‐Leo Hansmann, Dieter Kube, Pathology and Analyte Preparation (WP2-3), Siegfried Haas, Wolfgang Hiddemann, Ulrike Kostezka, Peter Möller, Andreas Rosenwald, German Ott, Monika Szczepanowski, Sequencing and genomics (WP4-7), Ole Ammerpohl, Sietse Aukema, Vera Binder, Arndt Borkhardt, Andrea Haake, Jessica I. Hoell, Ellen Leich, Peter Lichter, Cristina López, Inga Nagel, Jordan Pischimariov, Bernhard Radlwimmer and 27 more - Nature Communications 2022 cited by 140